ATE479760T1 - Universelles signalpeptid gas1 - Google Patents

Universelles signalpeptid gas1

Info

Publication number
ATE479760T1
ATE479760T1 AT05729650T AT05729650T ATE479760T1 AT E479760 T1 ATE479760 T1 AT E479760T1 AT 05729650 T AT05729650 T AT 05729650T AT 05729650 T AT05729650 T AT 05729650T AT E479760 T1 ATE479760 T1 AT E479760T1
Authority
AT
Austria
Prior art keywords
heavy chain
chain variable
variable domain
immunoglobulin heavy
domain polypeptide
Prior art date
Application number
AT05729650T
Other languages
English (en)
Inventor
Wildt Rudolph De
Original Assignee
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domantis Ltd filed Critical Domantis Ltd
Application granted granted Critical
Publication of ATE479760T1 publication Critical patent/ATE479760T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/055—Fusion polypeptide containing a localisation/targetting motif containing a signal for localisation to secretory granules (for exocytosis)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Gas Separation By Absorption (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT05729650T 2004-03-24 2005-03-24 Universelles signalpeptid gas1 ATE479760T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55576404P 2004-03-24 2004-03-24
PCT/GB2005/001180 WO2005093074A1 (en) 2004-03-24 2005-03-24 Gas1 universal leader

Publications (1)

Publication Number Publication Date
ATE479760T1 true ATE479760T1 (de) 2010-09-15

Family

ID=34963448

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05729650T ATE479760T1 (de) 2004-03-24 2005-03-24 Universelles signalpeptid gas1

Country Status (11)

Country Link
US (1) US7846721B2 (de)
EP (2) EP1737962B1 (de)
AT (1) ATE479760T1 (de)
CY (1) CY1111063T1 (de)
DE (1) DE602005023291D1 (de)
DK (1) DK1737962T3 (de)
ES (1) ES2351509T3 (de)
PL (1) PL1737962T3 (de)
PT (1) PT1737962E (de)
SI (1) SI1737962T1 (de)
WO (1) WO2005093074A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5185624B2 (ja) 2004-12-02 2013-04-17 ドマンティス リミテッド 血清アルブミンおよびｇｌｐ−１またはｐｙｙを標的とする二重特異性抗体
CA2688434A1 (en) 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
CN102307897B (zh) 2008-12-05 2016-01-20 葛兰素集团有限公司 选出蛋白酶抗性多肽的方法
AR075505A1 (es) 2009-02-19 2011-04-06 Glaxo Group Ltd Variantes de union a anti- albumina de suero mejoradas
MX2011008799A (es) 2009-02-19 2011-09-27 Glaxo Group Ltd Polipeptidos, dominios variables de anticuerpos, y antagonistas anti-tnfr1 mejorados.
CN105061593B (zh) 2009-02-19 2018-08-03 葛兰素集团有限公司 改良的抗血清清蛋白结合变体
JP2012532619A (ja) 2009-07-16 2012-12-20 グラクソ グループ リミテッド Ｔｎｆｒ１を部分的に阻害するためのアンタゴニスト、用途および方法
WO2011006915A2 (en) 2009-07-16 2011-01-20 Glaxo Group Limited Improved anti-serum albumin binding single variable domains
MX2012001278A (es) 2009-07-29 2012-03-16 Glaxo Group Ltd Anticuerpos de dominio simple anti-receptor tgf-beta tipo ii.
EP2523686A2 (de) 2010-01-14 2012-11-21 Glaxo Group Limited Auf die leber gerichtete domänen-antikörper
CA2796932A1 (en) 2010-04-21 2011-10-27 Glaxo Group Limited Binding domains
SG185437A1 (en) 2010-05-20 2012-12-28 Glaxo Group Ltd Improved anti-serum albumin binding variants
CN103228796B (zh) * 2010-08-11 2016-06-01 赛路拉公司 基因分型dna
EP2603522A1 (de) 2010-08-13 2013-06-19 GlaxoSmithKline Intellectual Property Development Limited Verbesserte antiserumalbuminbindende varianten
CA2808683A1 (en) 2010-08-20 2012-02-23 Glaxosmithkline Intellectual Property Development Limited Improved anti-serum albumin binding variants
US9150651B2 (en) 2011-01-06 2015-10-06 Glaxo Group Limited Single variable domain immunoglobulins that bind TGF-beta receptor II
JP2014505698A (ja) 2011-02-02 2014-03-06 グラクソ グループ リミテッド 新規抗原結合タンパク質
NO2699601T3 (de) 2011-04-21 2018-06-16
PL2870247T3 (pl) * 2012-07-05 2019-10-31 Hoffmann La Roche Układ ekspresji i wydzielania
WO2015134988A1 (en) 2014-03-07 2015-09-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9400600A (pt) * 1994-02-17 1995-10-24 Finep Financiadora De Estudos Processos para produção de uma protéina recombinante e/ou de glicosilfosfatidilinositol (GPI) em células de microorganismos eucariontes e para a obtenção de leveduras de S. cerevisae; célula de levedura sequência de nucleotídios; meio de cultura; medicamento ou vacina; e produto dos ditos processos
US6555310B1 (en) * 1997-04-04 2003-04-29 Biosite Diagnostics, Inc. Polyclonal libraries
US7094579B2 (en) * 2002-02-13 2006-08-22 Xoma Technology Ltd. Eukaryotic signal sequences for prokaryotic expression

Also Published As

Publication number Publication date
WO2005093074A1 (en) 2005-10-06
ES2351509T3 (es) 2011-02-07
DK1737962T3 (da) 2010-12-13
EP2172553A1 (de) 2010-04-07
US20070026462A1 (en) 2007-02-01
DE602005023291D1 (de) 2010-10-14
EP1737962A1 (de) 2007-01-03
PT1737962E (pt) 2010-12-03
PL1737962T3 (pl) 2011-02-28
CY1111063T1 (el) 2015-06-11
SI1737962T1 (sl) 2011-01-31
EP1737962B1 (de) 2010-09-01
US7846721B2 (en) 2010-12-07

Similar Documents

Publication Publication Date Title
CY1111063T1 (el) Καθολικος οδηγος gas1
DK1831362T3 (da) Syreaktive svampeproteaser
PT1523496E (pt) Produção de misturas de anticorpos de forma recombinante
NZ734307A (en) Antibodies specific for claudin 6 (cldn6)
ATE503009T1 (de) Polypeptide mit lipase-aktivität und diese kodierende polynukleotide
EA200701443A1 (ru) Синтетические домены иммуноглобулина, обладающие свойствами связывания и сконструированные в участках молекулы, отличных от гипервариабельных участков
JP2014061000A5 (de)
WO2006116657A3 (en) Single-chain antibody with cleavable linker
DE60333793D1 (de) Feste oberfläche für biomolekülabgabe und assay mit hoher durchlaufleistung
WO2008005847A3 (en) Method of producing factor viii proteins by recombinant methods
ATE513907T1 (de) Polypeptide mit endoglucanase-aktivität und polynukleotide zu ihrer kodierung
ATE512980T1 (de) Polypeptide mit beta-glucosidase-aktivität sowie diese codierende polynukleotide
ATE446972T1 (de) Il-1 bindende antikörper und fragmente davon
ATE515488T1 (de) Click-chemie zur herstellung von reportermolekülen
DK1294876T3 (da) EV-VEGF-nukleinsyrer og -polypeptider samt fremgangsmåder til deres benyttelse
WO2009088924A3 (en) Methods and materials for targeted affinity enhancement
WO2009023386A3 (en) Binding peptides having a c-terminally disposed specific binding domain
DK1609863T3 (da) Udskilte polypeptider og transmembranpolypeptider samt nucleinsyrer kodende for disse
DE502006009060D1 (de) Verfahren zur fermentativen Herstellung von Antikörpern
WO2006053021A3 (en) Methods for engineering polypeptide variants via somatic hypermutation and polypeptides made thereby
DK2261327T3 (da) Nye enantioselektive mikrobielle nitrilhydrataser med bred substratspecificitet
ATE539163T1 (de) Auf der verwendung von mva beruhende impfstoffe
DE602006010051D1 (de) Polypeptide mit endoglucanase-aktivtät und dafür codierende polynukleotide
DE60232346D1 (de) Verfahren zur weithin ungestützten verbrennung von petroleumkoks
WO2008008182A3 (en) Method of production of para-hydroxycinnamic acid

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1737962

Country of ref document: EP